t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
Company profile
Ticker
TTOO
Exchange
Website
CEO
John Sperzel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
T2 Biosystems Securities Corporation ...
TTOO stock data
Latest filings (excl ownership)
RW
Registration withdrawal request
14 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
14 May 24
FWP
Free writing prospectus
7 May 24
8-K
Other Events
7 May 24
FWP
Free writing prospectus
6 May 24
FWP
Free writing prospectus
6 May 24
S-1/A
IPO registration (amended)
6 May 24
8-K
T2 Biosystems Announces First Quarter 2024 Financial Results
6 May 24
10-Q
2024 Q1
Quarterly report
6 May 24
S-1/A
IPO registration (amended)
6 May 24
Transcripts
TTOO
Earnings call transcript
2024 Q1
6 May 24
TTOO
Earnings call transcript
2023 Q4
15 Feb 24
TTOO
Earnings call transcript
2023 Q3
12 Oct 23
TTOO
Earnings call transcript
2023 Q2
7 Aug 23
TTOO
Earnings call transcript
2023 Q2
7 Aug 23
TTOO
Earnings call transcript
2023 Q1
23 May 23
TTOO
Earnings call transcript
2022 Q4
13 Mar 23
TTOO
Earnings call transcript
2022 Q3
11 Nov 22
TTOO
Earnings call transcript
2022 Q2
16 Aug 22
TTOO
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
SC 13D/A
CR Group L.P.
13 May 24
4
Change in insider ownership
13 May 24
SC 13D/A
CR Group L.P.
7 May 24
4
Change in insider ownership
7 May 24
SC 13D
CR Group L.P.
19 Apr 24
4
Change in insider ownership
16 Apr 24
SC 13G
Safier Jacob
11 Mar 24
SC 13G
New Dimensions Trading
11 Mar 24
4
John J Sperzel III
27 Feb 24
4
John M Sprague
27 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.80 mm | 6.80 mm | 6.80 mm | 6.80 mm | 6.80 mm | 6.80 mm |
Cash burn (monthly) | 3.13 mm | 325.00 k | 4.20 mm | 4.05 mm | 3.89 mm | 3.91 mm |
Cash used (since last report) | 4.95 mm | 513.48 k | 6.64 mm | 6.40 mm | 6.15 mm | 6.17 mm |
Cash remaining | 1.85 mm | 6.29 mm | 164.31 k | 404.33 k | 647.24 k | 627.89 k |
Runway (months of cash) | 0.6 | 19.3 | 0.0 | 0.1 | 0.2 | 0.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 47 |
Opened positions | 22 |
Closed positions | 10 |
Increased positions | 13 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 7.62 bn |
Total shares | 100.77 mm |
Total puts | 277.00 k |
Total calls | 234.40 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
CR | 72.50 mm | $5.15 mm |
Vanguard | 5.88 mm | $1.30 bn |
Goldman Sachs & Co | 4.36 mm | $5.41 mm |
BLK Blackrock | 3.70 mm | $816.51 mm |
Aisling Capital Iii | 2.83 mm | $0.00 |
Gsa Capital Partners | 2.58 mm | $570.00 k |
Geode Capital Management | 2.41 mm | $531.57 mm |
Flagship Ventures Fund 2004 L P | 1.63 mm | $0.00 |
Lind Global Fund II | 1.02 mm | $815.00 k |
Jane Street | 646.89 k | $142.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 May 24 | CR | Common Stock | Conversion | Acquire C | Yes | No | 0 | 108,752 | 0.00 | 4,704,729 |
9 May 24 | CR | Common Stock | Conversion | Acquire C | Yes | No | 0 | 1,716,048 | 0.00 | 4,595,977 |
9 May 24 | CR | Series B Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 10,875.25 | 0.00 | 0 |
9 May 24 | CR | Series A Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 17,160.48 | 0.00 | 0 |
3 May 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 2,001,514 | 0.00 | 2,879,929 |
3 May 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,565,445 | 0.00 | 3,548,707 |
3 May 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 129,629 | 0.00 | 266,038 |
3 May 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 403,608 | 0.00 | 828,324 |
3 May 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 648,139 | 0.00 | 1,330,175 |
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 390,142 | 0.00 | 878,415 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
16 May 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
15 May 24
Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
7 May 24
T2 Biosystems Reiterates Guidance
6 May 24
T2 Biosystems Q1 2024 GAAP EPS $(2.66) Misses $(2.27) Estimate, Sales $2.061M Beat $2.000M Estimate
6 May 24
Press releases
T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
17 May 24
Treatment.com AI Inc (CSE: TRUE) Partners with Novus Health to Support Over 1.5 Million Members and Families
16 May 24
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
15 May 24
T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock
14 May 24
T2 Biosystems Announces First Quarter 2024 Financial Results
6 May 24